+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Protein Binding Assays Market Size, Share & Trends Analysis Report By Technology (Equilibrium Dialysis), By Product & Services (Instruments), By End Use (Pharmaceutical & Biotechnology Companies), By Region, And Segment Forecasts, 2019 - 2026

  • ID: 4871374
  • Report
  • September 2019
  • Region: Global
  • 188 Pages
  • Grand View Research

FEATURED COMPANIES

  • 3B Pharmaceuticals
  • Absorption Systems LLC
  • BioDuro
  • Charles River
  • Creative Biolabs
  • Cyprotex
The global protein binding assays market size is expected to reach USD 683.09 million by 2026 at a CAGR of 10.6%, according to this report. Protein binding assays are increasingly being adopted in preclinical stages of drug discovery & development programs. These assays help in detection of target molecules and provide critical information about the properties of therapeutics and biologics.

Increase in number of R&D outsourcing activities by pharmaceutical companies for development of therapeutics is anticipated to increase the adoption of protein binding assays. Presence of several companies that provide these services for molecule investigation and analysis is expected to positively impact the market growth over the forecast period.

These assays provide help understand ADME properties during selection and development of therapeutic candidates. Estimation of safety margins during drug development is an important step that can be carried out by quantification of binding of new chemical entities to a protein.

Further key findings from the report suggest:
  • Equilibrium dialysis accounted for the largest share and is expected to maintain its dominance over the forecast period

  • This is because equilibrium dialysis is an extensively used method to detect free drug fraction as it is less susceptible to experimental artifacts

  • Instruments segment is expected to grow at the fastest CAGR due to rising demand for automated, user-friendly systems that help determine the distribution capacity of drug candidates

  • Assay services offered by a large number of biotechnology players can be attributed to the segment’s largest revenue share in 2018

  • Increase in number of CROs offering customized, comprehensive, and economical protein binding assay services to support pharmaceutical firms is expected to boost growth of CROs segment

  • Pharmaceutical firms are investing significantly in preclinical drug discovery studies to meet the growing demand for therapeutics resulting in the largest protein binding assays market share of the segment

  • Presence of leading players providing such assays and high R&D investment for therapeutic development can be attributed to the dominant share of North America

  • Asia Pacific is expected to witness fastest growth due to low cost of preclinical methods, which increases outsourcing of services to the region

  • Companies such as Thermo Fisher, Charles River, Sovicell, GE Healthcare, Evotec, and others have undertaken several strategic initiatives to enhance their market presence


This product will be delivered within 1-3 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 3B Pharmaceuticals
  • Absorption Systems LLC
  • BioDuro
  • Charles River
  • Creative Biolabs
  • Cyprotex

Chapter 1 Executive Summary
1.1 Protein Binding Assays Market Outlook, 2015-2026
1.2 Protein Binding Assays Market: Segment Outlook, 2015-2026
1.3 Protein Binding Assays Market: Competitive Insights
Chapter 2 Research Methodology & Scope
2.1 Information Procurement
2.2 Information or Data Analysis
2.3 Market Formulation & Validation
Chapter 3 Protein Binding Assays Market Variables, Trends & Scope
3.1 Industry Pyramid Analysis
3.2 Penetration & Growth Prospect Mapping for Technology, 2018
3.3 Protein Binding Assays Market: Technology Overview
3.4 Protein Binding Assays Market: Market Dynamics
3.4.1 Market driver analysis
3.4.1.1 Increase in adoption of protein binding assays in drug discovery & development
3.4.1.2 High rate of late stage drug failure
3.4.1.3 Substantial number of CROs operating in the space
3.4.2 Market restraint analysis
3.4.2.1 Challenges pertaining to standardization of assay designing
3.4.3 Market challenges analysis
3.4.3.1 Introduction of in-silico prediction techniques
3.5 Industry Analysis-Porter’s
3.6 Protein Binding Assays Market-SWOT Analysis, by Factor (Political & Legal, Economic, And Technological)
3.7 Major Deals & Strategic Alliances Analysis
3.7.1 Mergers & acquisitions
3.7.2 Collaborations & partnership
3.7.3 Agreement
Chapter 4 Protein Binding Assays Market Categorization: Technology Estimates & Trend Analysis
4.1 Protein Binding Assays Market: Technology Movement Analysis, 2018 & 2026
4.2 Ultracentrifugation
4.2.1 Global protein binding assays market by ultracentrifugation, 2015-2026 (USD Million)
4.3 Equilibrium Dialysis
4.3.1 Global protein binding assays market by equilibrium dialysis, 2015-2026 (USD Million)
4.4 Ultrafiltration
4.4.1 Global protein binding assays market by ultrafiltration, 2015-2026 (USD Million)
4.5 Surface Plasmon Resonance
4.5.1 Global protein binding assays market by surface plasmon resonance, 2015-2026 (USD Million)
4.6 Other Technologies
4.6.1 Global protein binding assays market by other technologies, 2015-2026 (USD Million)
Chapter 5 Protein Binding Assays Market Categorization: Product & Service Estimates & Trend Analysis
5.1 Protein Binding Assays Market: Product & Service Movement Analysis, 2018 & 2026
5.2 Instruments
5.2.1 Global protein binding assays market by instruments, 2015-2026 (USD Million)
5.3 Kits & Reagents
5.3.1 Global protein binding assays market by kits & reagents, 2015-2026 (USD Million)
5.4 Services
5.4.1 Global protein binding assays market by services, 2015-2026 (USD Million)
Chapter 6 Protein Binding Assays Market Categorization: End Use & Trend Analysis
6.1 Protein Binding Assays Market: End-use Movement Analysis, 2018 & 2026
6.2 Contract Research Organizations
6.2.1 Global protein binding assays market for contract research organizations, 2015-2026 (USD Million)
6.3 Pharmaceutical & Biotechnology Companies
6.3.1 Global protein binding assays market for pharmaceutical & biotechnology companies, 2015-2026 (USD Million)
6.4 Other End Use
6.4.1 Global protein binding assays market for other end use, 2015-2026 (USD Million)
Chapter 7 Protein Binding Assays Market Categorization: Regional Estimates & Trend Analysis by Technology, Product & Services, & End Use
7.1 Protein Binding Assays Market Share by Region, 2018 & 2026
7.2 North America
7.2.1 North America protein binding assays market, 2015-2026 (USD Million)
7.2.2 U.S.
7.2.2.1 U.S. protein binding assays market, 2015-2026 (USD Million)
7.2.3 Canada
7.2.3.1 Canada protein binding assays market, 2015-2026 (USD Million)
7.3 Europe
7.3.1 Europe protein binding assays market, 2015-2026 (USD Million)
7.3.2 Germany
7.3.2.1 Germany protein binding assays market, 2015-2026 (USD Million)
7.3.3 U.K.
7.3.3.1 U.K. protein binding assays market, 2015-2026 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific protein binding assays market, 2015-2026 (USD Million)
7.4.2 Japan
7.4.2.1 Japan protein binding assays market, 2015-2026 (USD Million)
7.4.3 China
7.4.3.1 China protein binding assays market, 2015-2026 (USD Million)
7.5 Latin America
7.5.1 Latin America protein binding assays market, 2015-2026 (USD Million)
7.5.2 Brazil
7.5.2.1 Brazil Protein Binding Assays market, 2015-2026 (USD Million)
7.6 Middle East & Africa (MEA)
7.6.1 MEA protein binding assays market, 2015-2026 (USD Million)
7.6.2 South Africa
7.6.2.1 South Africa protein binding assays market, 2015-2026 (USD Million)
Chapter 8 Protein Binding Assays: Competitive Landscape
8.1 Company Categorization
8.2 Recent Developments & Impact Analysis, by Key Market Participants
8.3 Vendor Landscape
8.4 Public Companies
8.4.1 Company market position analysis
8.5 Private Companies
8.5.1 List of key emerging companies
8.6 Strategy Framework
8.7 Company Profiles
8.8.1 Charles River
8.8.1.1 Company overview
8.8.1.2 Financial performance
8.8.1.3 Product benchmarking
8.8.1.4 Strategic initiatives
8.8.2 Thermo Fisher Scientific, Inc.
8.8.2.1 Company overview
8.8.2.2 Financial performance
8.8.2.3 Product benchmarking
8.8.2.4 Strategic initiatives
8.8.3 Evotec
8.8.3.1 Company overview
8.8.3.2 Cyprotex
8.8.3.2.1 Company overview
8.8.3.3 Financial performance
8.8.3.4 Product benchmarking
8.8.3.5 Strategic initiatives
8.8.4 Sovicell GMBH
8.8.4.1 Company overview
8.8.4.1 Financial performance
8.8.4.2 Product benchmarking
8.8.4.3 Strategic initiatives
8.8.5 Absorption Systems LLC
8.8.5.1 Company overview
8.8.5.2 Financial performance
8.8.5.3 Product benchmarking
8.8.5.4 Strategic initiatives
8.8.6 GE Healthcare
8.8.6.1 Company overview
8.8.6.2 Financial performance
8.8.6.3 Product benchmarking
8.8.6.4 Strategic initiatives
8.8.7 Eurofins Scientific
8.8.7.1 Company overview
8.8.7.2 Financial performance
8.8.7.3 Product benchmarking
8.8.7.4 Strategic initiatives
8.8.8 3B Pharmaceuticals
8.8.8.1 Company overview
8.8.8.2 Financial performance
8.8.8.3 Product benchmarking
8.8.8.4 Strategic initiatives
8.8.9 Creative Biolabs
8.8.9.1 Company overview
8.8.9.2 Financial performance
8.8.9.3 Product benchmarking
8.8.9.4 Strategic initiatives
8.8.10 BioDuro
8.8.10.1 Company overview
8.8.10.2 Financial performance
8.8.10.3 Product benchmarking
8.8.10.4 Strategic initiatives
Note: Product cover images may vary from those shown
  • Charles River
  • Thermo Fisher Scientific, Inc.
  • Evotec
  • Cyprotex
  • Sovicell GMBH
  • Absorption Systems LLC
  • GE Healthcare
  • Eurofins Scientific
  • 3B Pharmaceuticals
  • Creative Biolabs
  • BioDuro
Note: Product cover images may vary from those shown

Loading
LOADING...